Search

Your search keyword '"van Eck-Smit B"' showing total 13 results
Start Over Author "van Eck-Smit B" Database OAIster
13 results on '"van Eck-Smit B"'

1. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients

Author

Kraal, K. C. J. M., Bleeker, G. M., van Eck-Smit, B. L. F., van Eijkelenburg, N. K. A., Berthold, F., van Noesel, M. M., Caron, H. N., Tytgat, G. A. M., Kraal, K. C. J. M., Bleeker, G. M., van Eck-Smit, B. L. F., van Eijkelenburg, N. K. A., Berthold, F., van Noesel, M. M., Caron, H. N., and Tytgat, G. A. M.

Abstract

Aim of the study: Radiolabelled meta-iodobenzylguanidine (MIBG) is an effective option in treatment of neuroblastoma (NBL) tumours. We studied feasibility, toxicity and efficacy of upfront 1311-MIBG and induction treatment in stage 4 NBL patients. Patients and methods: Retrospective, multi-centre (AMC and EMC) pilot regimen (1/1/2005 2011). Newly diagnosed stage 4 NBL patients, were treated with 2 courses of 1311-MIBG, GP01-1 2004 NBL protocol, myeloablative therapy (MAT) and autologous stem cell rescue (ASCT). 1311-MIBG was administered in a fixed dose. Response rate (RR) was defined as complete remission, very good partial response and partial response. Results: Thirty-two patients, (median age [range] 2.9 [0-11.4] years), 21 received 1311-MIBG therapy, 11 did not because of: MIBG non-avid (N = 5) and poor clinical condition (N = 6). In 95% of eligible patients I-131-MIBG treatment was feasible within 2 weeks from diagnosis. Interval between chemotherapy courses was 25 days (I-131-MIBG group) versus 22 days (chemotherapy group). No stem cell support was needed after I-131-MIBG therapy. Stem cell harvest in both groups was feasible, neutrophil recovery was comparable, but platelet recovery post MAT, ASCT was slower for I-131-MIBG-treated patients. RR post I-131-MIBG was 38%, post MAT + ASCT was 71% (I-131-MIBG group), 36% (chemotherapy group) and overall 59%. Conclusions: Induction therapy with I-131-MIBG before the HR GPOH NB 2004 protocol is feasible, tolerable and effective in newly diagnosed stage 4 NBL patients. I-131-MIBG upfront therapy induces early responses. (C) 2017 Elsevier Ltd. All rights reserved.

Published
2017

2. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients

Author

Kraal, K. C. J. M., Bleeker, G. M., van Eck-Smit, B. L. F., van Eijkelenburg, N. K. A., Berthold, F., van Noesel, M. M., Caron, H. N., Tytgat, G. A. M., Kraal, K. C. J. M., Bleeker, G. M., van Eck-Smit, B. L. F., van Eijkelenburg, N. K. A., Berthold, F., van Noesel, M. M., Caron, H. N., and Tytgat, G. A. M.

Abstract

Aim of the study: Radiolabelled meta-iodobenzylguanidine (MIBG) is an effective option in treatment of neuroblastoma (NBL) tumours. We studied feasibility, toxicity and efficacy of upfront 1311-MIBG and induction treatment in stage 4 NBL patients. Patients and methods: Retrospective, multi-centre (AMC and EMC) pilot regimen (1/1/2005 2011). Newly diagnosed stage 4 NBL patients, were treated with 2 courses of 1311-MIBG, GP01-1 2004 NBL protocol, myeloablative therapy (MAT) and autologous stem cell rescue (ASCT). 1311-MIBG was administered in a fixed dose. Response rate (RR) was defined as complete remission, very good partial response and partial response. Results: Thirty-two patients, (median age [range] 2.9 [0-11.4] years), 21 received 1311-MIBG therapy, 11 did not because of: MIBG non-avid (N = 5) and poor clinical condition (N = 6). In 95% of eligible patients I-131-MIBG treatment was feasible within 2 weeks from diagnosis. Interval between chemotherapy courses was 25 days (I-131-MIBG group) versus 22 days (chemotherapy group). No stem cell support was needed after I-131-MIBG therapy. Stem cell harvest in both groups was feasible, neutrophil recovery was comparable, but platelet recovery post MAT, ASCT was slower for I-131-MIBG-treated patients. RR post I-131-MIBG was 38%, post MAT + ASCT was 71% (I-131-MIBG group), 36% (chemotherapy group) and overall 59%. Conclusions: Induction therapy with I-131-MIBG before the HR GPOH NB 2004 protocol is feasible, tolerable and effective in newly diagnosed stage 4 NBL patients. I-131-MIBG upfront therapy induces early responses. (C) 2017 Elsevier Ltd. All rights reserved.

Published
2017

3. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients

Author

PMC Medisch specialisten, Kraal, K. C.J.M., Bleeker, G. M., van Eck-Smit, B. L.F., van Eijkelenburg, N. K.A., Berthold, F., van Noesel, M. M., Caron, H. N., Tytgat, G. A.M., PMC Medisch specialisten, Kraal, K. C.J.M., Bleeker, G. M., van Eck-Smit, B. L.F., van Eijkelenburg, N. K.A., Berthold, F., van Noesel, M. M., Caron, H. N., and Tytgat, G. A.M.

Published
2017

5. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma - A systematic review

Author

Clement, S C, Peeters, R P, Ronckers, C M, Links, T P, van den Heuvel-Eibrink, M M, Nieveen van Dijkum, E J M, van Rijn, R R, van der Pal, H J H, Neggers, S J, Kremer, L C M, van Eck-Smit, B L F, van Santen, H M, Clement, S C, Peeters, R P, Ronckers, C M, Links, T P, van den Heuvel-Eibrink, M M, Nieveen van Dijkum, E J M, van Rijn, R R, van der Pal, H J H, Neggers, S J, Kremer, L C M, van Eck-Smit, B L F, and van Santen, H M

Published
2015

7. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma - A systematic review

Author

Clement, S C, Peeters, R P, Ronckers, C M, Links, T P, van den Heuvel-Eibrink, M M, Nieveen van Dijkum, E J M, van Rijn, R R, van der Pal, H J H, Neggers, S J, Kremer, L C M, van Eck-Smit, B L F, van Santen, H M, Clement, S C, Peeters, R P, Ronckers, C M, Links, T P, van den Heuvel-Eibrink, M M, Nieveen van Dijkum, E J M, van Rijn, R R, van der Pal, H J H, Neggers, S J, Kremer, L C M, van Eck-Smit, B L F, and van Santen, H M

Published
2015

8. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma - A systematic review

Author

Clement, S C, Peeters, R P, Ronckers, C M, Links, T P, van den Heuvel-Eibrink, M M, Nieveen van Dijkum, E J M, van Rijn, R R, van der Pal, H J H, Neggers, S J, Kremer, L C M, van Eck-Smit, B L F, van Santen, H M, Clement, S C, Peeters, R P, Ronckers, C M, Links, T P, van den Heuvel-Eibrink, M M, Nieveen van Dijkum, E J M, van Rijn, R R, van der Pal, H J H, Neggers, S J, Kremer, L C M, van Eck-Smit, B L F, and van Santen, H M

Published
2015

10. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma - A systematic review

Author

Endocrinologie patientenzorg, Child Health, Endocrinologie onderzoek, Clement, S C, Peeters, R P, Ronckers, C M, Links, T P, van den Heuvel-Eibrink, M M, Nieveen van Dijkum, E J M, van Rijn, R R, van der Pal, H J H, Neggers, S J, Kremer, L C M, van Eck-Smit, B L F, van Santen, H M, Endocrinologie patientenzorg, Child Health, Endocrinologie onderzoek, Clement, S C, Peeters, R P, Ronckers, C M, Links, T P, van den Heuvel-Eibrink, M M, Nieveen van Dijkum, E J M, van Rijn, R R, van der Pal, H J H, Neggers, S J, Kremer, L C M, van Eck-Smit, B L F, and van Santen, H M

Published
2015

11. Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during I-131-metaiodobenzylguanidine treatment in children with neuroblastoma

Author

Endocrinologie patientenzorg, Child Health, Endocrinologie onderzoek, PMC Medisch specialisten, Clement, S. C., van Rijn, R. R., van Eck-Smit, B. L. E., van Trotsenburg, A. S. P., Caron, H. N., Tytgat, G. A. M., van Santen, H. M., Endocrinologie patientenzorg, Child Health, Endocrinologie onderzoek, PMC Medisch specialisten, Clement, S. C., van Rijn, R. R., van Eck-Smit, B. L. E., van Trotsenburg, A. S. P., Caron, H. N., Tytgat, G. A. M., and van Santen, H. M.

Published
2015

12. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology

Author

Hesse, B., Tägil, K., Cuocolo, A., Anagnostopoulos, C., Bardiés, M., Bax, J., Bengel, F., Sokole, E. Busemann, Davies, G., Dondi, M., Edenbrandt, L., Franken, P., Kjaer, A., Knuuti, J., Lassmann, M., Ljungberg, M., Marcassa, C., Marie, P. Y., McKiddie, F., O'Connor, M., Prvulovich, E., Underwood, R., Van Eck-Smit, B., Hesse, B., Tägil, K., Cuocolo, A., Anagnostopoulos, C., Bardiés, M., Bax, J., Bengel, F., Sokole, E. Busemann, Davies, G., Dondi, M., Edenbrandt, L., Franken, P., Kjaer, A., Knuuti, J., Lassmann, M., Ljungberg, M., Marcassa, C., Marie, P. Y., McKiddie, F., O'Connor, M., Prvulovich, E., Underwood, R., and Van Eck-Smit, B.

Abstract

The European procedural guidelines for radionuclide imaging of myocardial perfusion and viability are presented in 13 sections covering patient information, radiopharmaceuticals, injected activities and dosimetry, stress tests, imaging protocols and acquisition, quality control and reconstruction methods, gated studies and attenuation-scatter compensation, data analysis, reports and image display, and positron emission tomography. If the specific recommendations given could not be based on evidence from original, scientific studies, we tried to express this state-of-art. The guidelines are designed to assist in the practice of performing, interpreting and reporting myocardial perfusion SPET. The guidelines do not discuss clinical indications, benefits or drawbacks of radionuclide myocardial imaging compared to non-nuclear techniques, nor do they cover cost benefit or cost effectiveness.

Published
2005

13. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology

Author

Hesse, B., Tägil, K., Cuocolo, A., Anagnostopoulos, C., Bardiés, M., Bax, J., Bengel, F., Sokole, E. Busemann, Davies, G., Dondi, M., Edenbrandt, L., Franken, P., Kjaer, A., Knuuti, J., Lassmann, M., Ljungberg, M., Marcassa, C., Marie, P. Y., McKiddie, F., O'Connor, M., Prvulovich, E., Underwood, R., Van Eck-Smit, B., Hesse, B., Tägil, K., Cuocolo, A., Anagnostopoulos, C., Bardiés, M., Bax, J., Bengel, F., Sokole, E. Busemann, Davies, G., Dondi, M., Edenbrandt, L., Franken, P., Kjaer, A., Knuuti, J., Lassmann, M., Ljungberg, M., Marcassa, C., Marie, P. Y., McKiddie, F., O'Connor, M., Prvulovich, E., Underwood, R., and Van Eck-Smit, B.

Abstract

The European procedural guidelines for radionuclide imaging of myocardial perfusion and viability are presented in 13 sections covering patient information, radiopharmaceuticals, injected activities and dosimetry, stress tests, imaging protocols and acquisition, quality control and reconstruction methods, gated studies and attenuation-scatter compensation, data analysis, reports and image display, and positron emission tomography. If the specific recommendations given could not be based on evidence from original, scientific studies, we tried to express this state-of-art. The guidelines are designed to assist in the practice of performing, interpreting and reporting myocardial perfusion SPET. The guidelines do not discuss clinical indications, benefits or drawbacks of radionuclide myocardial imaging compared to non-nuclear techniques, nor do they cover cost benefit or cost effectiveness.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results